Free tool
FAERS Monitor: Qelbree
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211964 or its brand name (Qelbree, Viloxazine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,309
Serious
400
31% of reports
Hospitalization
86
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache146
- vomiting132
- nausea130
- migraine124
- fatigue109
- insomnia109
- somnolence87
- drug ineffective82
- suicidal ideation82
- withdrawal syndrome57
- anxiety56
- product dose omission issue51
- depression45
- anger44
- dizziness44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 4 |
| 2020 | 1 |
| 2021 | 53 |
| 2022 | 215 |
| 2023 | 204 |
| 2024 | 186 |
| 2025 | 285 |
| 2026 | 361 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,850 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| withdrawal syndromeSignal | 57 | 21.8 | 16.9 | 1,113 |
| angerSignal | 44 | 20.9 | 15.7 | 816 |
| migraineSignal | 124 | 20.9 | 17.7 | 2,337 |
| suicidal ideationSignal | 82 | 14.4 | 11.7 | 1,013 |
| somnolenceSignal | 87 | 6.9 | 5.7 | 441 |
| insomniaSignal | 109 | 6.6 | 5.5 | 516 |
| vomitingSignal | 132 | 4.5 | 3.8 | 365 |
| headacheSignal | 146 | 3.7 | 3.2 | 300 |
| depressionSignal | 45 | 3.2 | 2.4 | 66 |
| anxietySignal | 56 | 3.2 | 2.4 | 82 |
| product dose omission issueSignal | 51 | 2.8 | 2.1 | 57 |
| nauseaSignal | 130 | 2.6 | 2.2 | 136 |
| fatigueSignal | 109 | 2.2 | 1.9 | 77 |
| dizziness | 44 | 1.4 | 1.1 | 5 |
| drug ineffective | 82 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.